pharmind Pharm. Ind. 76, Nr.9 2014
Drug development inarguably is a risky business, especially for biotech companies pursuing novel approaches, and having only a small portfolio further aggravates overall risk of failure at a corporate level. Being able to carry out a standardised, fact-based evaluation of development candidates becomes a crucial factor for decision-making in many contexts e. g. internal portfolio investments, fund-raising, deciding on a project strategy or preparing for out-licensing.